You are viewing the site in preview mode

Skip to main content

Table 1 Changes in serum markers in patients with different treatment time to remission

From: Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study

  Remission time
 < 6 months (n = 19) 		Remission time
 ≥ 6 months (n = 31) 		p-value
T0-Estradiol, pg/mL 105.2 ± 187.2 53.1 ± 83.9 0.322
T0-FSH, IU/L 5.5 ± 2.3 5.3 ± 3.1 0.831
T0-LH, IU/L 3.0 ± 2.1 3.8 ± 3.2 0.494
T0-T, nmol/L 1.0 ± 0.6 0.9 ± 0.7 0.672
T0-PRL, ng/mL 20.3 ± 11.2 21.0 ± 9.6 0.437
T0-HOMA-IR 2.2 ± 1.3 4.2 ± 2.0 0.004
T1-HOMA-IR 2.4 ± 1.5 3.6 ± 3.7 0.311
T2-HOMA-IR 2.7 ± 1.8 4.0 ± 2.9 0.185
T1 vs. T0-HOMA-IR − 12% − 39% 0.049
T2 vs. T0-HOMA-IR 25% − 44% 0.020
T0-HbA1c, % 5.7 ± 0.4 5.6 ± 0.4 0.922
T0-FT4, pmol/L 16.4 ± 2.8 16.8 ± 1.9 0.688
T0-TSH, uIU/mL 2.1 ± 1.7 2.2 ± 0.9 0.864
  1. Bold part represents p-value less than or near 0.05
  2. E, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; T, testosterone; PRL, prolactin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, glycosylated hemoglobin A1c; FT4, free thyroxine; TSH, thyroid-stimulating hormone
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us